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Executive Summary 
 
Previous research on voluntary counselling and testing for HIV has shown a wide range of 
unit costs at fixed testing sites.  In this study, we report on the unit costs of an innovative 
mobile screening program in Namibia (Bophelo!) which combined HIV screening with tests 
for eight other diseases or risk factors.  These results are compared with unit costs for the 
fixed site Voluntary Counselling and Testing (VCT) program in Namibia, New Start, which is 
sponsored by United States Agency for International Development (USAID). 
 
Bophelo! was created as a public private partnership between PharmAccessNamibia, the 
Namibian Business Coalition on AIDS (NABCOA) and the Namibian Institute of Pathology 
(NIP).  After receiving clinic licenses from the Ministry of Health and Social Services in 
Namibia, the Bophelo! coalition began operating two mobile testing vans in 2009.  The 
vans, which each house two counselling rooms, travelled to employment sites, and later 
remote farms and tourist lodges.  There, employees were tested for HIV, cholesterol, 
blood glucose and haemoglobin levels, hepatitis B, syphilis, and hypertension.  They were 
also asked screening questions for tuberculosis (TB).  Employers paid a fee for the 
Bophelo! clinics to conduct on-site testing.  Most of the remainder of Bophelo! costs were 
supported by a grant from the Global Fund. 
 
Funded by USAID, IntraHealth operated a network of 18 fixed site New Start HIV testing 
centers throughout Namibia. Twelve of these are free standing sites while a further six are 
located on the premises of public or mission health providers.  Testing at the sites is free, 
but patients must pay to travel to the site.  In addition to HIV counselling and testing, New 
Start refers pregnant HIV positive women for Prevention of Mother to Child Transmission 
PTMCT (PMTCT) and asks screening questions on TB, STI’s and alcohol abuse. 
 
Data were collected on patient volumes and costs at both New Start and Bophelo! for the 
full year 2009.  Because Bophelo! was not in full operation until March of 2009, the 
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comparison below covers the full year for New Start and the period March to December 
2009 for Bophelo!. 
 
 
Table 1: Summary 
 Bophelo! New Start 
Number testing for 
HIV 
5,124 1 70,1432 
Percent male 64.2% 42.9% 
Number testing for 
HIV for first time 
1,182 N.A. 
Number testing HIV positive    537 7,365 
Total Cost $310,451 $4,082,936 
Private Contribution 
(employer payments) 
$116,993 ---------- 
Net public/donor costs $193,458 $4,082,936 
Cost per person tested for HIV $ 60.59 $58.21 
Cost per person testing for 
HIV for first time 
$262.65 N.A. 
Cost per person testing positive 
For HIV 
$578.12 $557.09 
Public cost per person tested $37.76 $58.21 
Public cost per person tested  
for HIV for first time 
$163.67   N.A. 
Public cost per person testing  
HIV positive 
$360.26 $557.09 
 
Costs shown are in US dollars 
 
The above summary shows that the mobile testing program was only slightly more 
expensive for each person tested than the fixed site testing program.  This difference was 
largely explained by a difference in price for VCT testing kits, which were available less 
expensively to New Start through the USAID sponsored Supply Chain Management 
System. Employers paid for over one third of Bophelo! costs, so the public sector costs per 
person tested by Bophelo! were substantially lower than those at New Start.  The patients 
screened incurred no costs at Bophelo!, since the clinic came to the work site and those 
being tested did not have to pay for travel or take time off from work. 
 
At an incremental cost of only US$11.35 (18.7%), Bophelo! screened for the eight 
additional diseases and conditions besides HIV.  Over half of persons (50.6%) tested had at 
least one of these conditions.  All patients were referred for follow up care----those who 
were insured to private doctors, others to Ministry of Health and Social Services(MoHSS) 
facilities. 
 
                                                     
1
 All data for Bophelo! for period March to December 2009 
2
 All New Start data for twelve months, January to December 2009 
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The study shows the advantages of both mobile multi-disease screening and a strong 
public private partnership.  Proportionately more men were reached by Bophelo!.  In part, 
this is because the work force at the sites visited was disproportionately male.  But the 
convenience of testing at work, and the fact that eight conditions in addition to HIV were 
screened, may have induced men to test who thought they were not at risk of HIV 
infection, or who would be reluctant  to seek out an HIV testing site.   
 
Those tested by Bophelo! incurred no out of pocket costs.  When Bophelo! shifted to 
testing at remote farms and tourist lodges in November and December 2009, unit costs 
were somewhat higher,  but the proportion testing for the first time was also much 
higher.  Bophelo! was reaching those reluctant to test or unable to do so because of the 
cost and difficulty of travelling to a fixed testing site.  
 
The public/private partnership embodied in Bophelo! mobilized employer funds, reducing 
the public/donor cost per test below that for the New Start facilities.  The management 
flexibility inherent in private sector operation likely contributed to controlling unit costs.  
Bophelo! appears to be a useful model to screen populations for HIV and other critical 
chronic diseases anywhere in Africa, but particularly where formal sector employment is 
substantial and some populations are remote and difficult to reach.    
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1. Background 
1.1. Introduction 
The Bophelo! partnership consists of PharmAccess Foundation, the Namibia Business 
Coalition on AIDS (NABCOA) and the Namibian Institute of Pathology (NIP). Since the 
beginning of 2009, two mobile clinics run by this partnership have been in operation to 
provide wellness testing for companies in Namibia. The program is unique both because it 
provides mobile screening for a number of conditions including HIV infection, and because 
it is supported by both public funds and private (employer paid) user fees.  There is an 
interest from the partners as well as the wider national and international health 
community to evaluate the unit costs and funding of this mobile multi-disease screening 
program in Namibia, and where possible, to provide a comparison with the costs of fixed 
site testing. 
 
1.2. Study questions 
The study addresses the following questions: 
 
 What is the full cost of operating a mobile, multi disease screening program in 
Namibia?   
 A full cost analysis will show the cost per unit for each of the following measures: 
 Cost per patient (all patients screened) 
 Cost per patient screened for HIV3 
 Cost per patient screened for the first time for HIV 
 Cost per patient newly identified as HIV positive 
 
 What is the value of the private (employer fee) and public (donors and Namibian 
Government) contributions to the cost of the Bophelo! program?  
 
 Is mobile screening more or less efficient than fixed site screening for HIV infection?  
 
 Is Bophelo! more effective at reaching out to groups that are unlikely to seek VCT?  
We hypothesize that the mobile multi-disease screening approach may attract 
many who have not tested before for HIV, or who do not believe they are at risk 
for the disease. Data on “first time testers” can be used to examine this 
hypothesis. 
 
 
 
 
 
 
                                                     
3
 Some patients decline the HIV test but accept screening for other diseases/conditions in the mobile Bophelo! 
clinic.  Anecdotally, we know that a number of those who decline already know that they are HIV positive, 
and some are in treatment. 
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1.3. Bophelo! 
Since 2006, PharmAccess Foundation, in collaboration with the Namibian Business 
Coalition on AIDS (NABCOA) and the Namibian Institute of Pathology (NIP), has conducted 
anonymous HIV seroprevalence surveys of Namibian workers.  The three organizations are 
referred to hereafter as the Bophelo! partners (“the Partners”). The surveys were 
conducted at employment sites and paid for by the employers.  After reviewing the results 
of these tests, the Partners concluded that there was a need to bring VCT to Namibian 
employment sites. Under the regulations of the MOHSS, VCT can only be conducted at a 
licensed clinic/rapid testing site.  The Partners decided to create mobile testing clinics 
which would meet MOHSS licensing requirements.  They also decided to include screening 
for a wider range of diseases.  In this way, a patient would not be identifying him or 
herself as being at risk for HIV infection, as might be the case in attending a VCT clinic.  It 
was hoped that this would reduce stigma and increase uptake of counselling and 
screening. 
 
The partners initially created the Bophelo! project, using funding from the Dutch Postcode 
Loterij and the Global Fund for AIDS, TB and Malaria (GFATM).  The terms of the 
Partnership are documented in a Memorandum of Understanding signed by the partners 
in December 2009 and attached as Appendix One.  PharmAccess and NABCOA each built a 
mobile screening van to a common design, mounted on a truck chassis, and containing 
two examination rooms, toilet facilities and all of the equipment necessary to provide 
patient education and confidential counselling and conduct screening tests for the 
following conditions: 
 Hypertension (blood pressure) 
 Elevated glucose levels (rapid test) 
 Elevated cholesterol (rapid test) 
 Haemoglobin levels (rapid test) 
 Weight, height, waist circumference and body mass index 
 HIV (rapid test) 
 Hepatitis B (rapid test) 
 Syphilis (rapid test) 
 TB (symptom screening questions) 
 
At the beginning of 2009, MOHSS granted conditional licenses to the two Bophelo! vans, 
and they began visits to Namibian employment sites.  PharmAccess employed the testing 
and counselling staff, and scheduled and managed the vans.  NABCOA provided outreach 
services to encourage companies to use the Bophelo! van.  NIP provided quality 
assurance, including retesting of a 5% sample of on-site results.  Employers pay a fee, 
while the Global Fund covers the remainder of the cost for PharmAccess and NABCOA.  
NIP is currently contributing its quality control services to the partnership. In addition, 
funding from donors was obtained through the Dutch government to kick start the 
project. 
 
As part of the Bophelo! screening process, PharmAccess collects a number of data 
elements on socioeconomic and risk factors for each person screened.  This information, 
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along with all of the test results, is entered into a database maintained by PharmAccess.  
Individual identifiers are not included in the database, the data is fully anonymous.  By 
mid-December 2009, around 6,000 people had been screened by the Bophelo! vans, with 
data on identified conditions and risk factors entered into the database.   
 
In November 2009, the Bophelo! vans moved beyond concentrated employment sites and 
began a pilot screening at remote farms and tourist facilities in Namibia. During this pilot, 
the dependents of the farm workers were also offered screening. In contrast to providing 
testing at companies in urban surroundings, the circumstances in the rural area were 
quite different, leading to high transport costs due to the longer distances. 
 
Patients who test positive for any condition are urged to seek follow up consultation and 
care.  Those with medical scheme coverage are encouraged to see a private provider. 
Clients that need further treatment are given a standard MOHSS referral letter.  The 
referral letter indicates the condition(s) detected.  In addition, the Bophelo! counselor 
gives the patient a form coded with the same number as the testing information but 
without identifying information, which is meant for the employer. This form does not 
identify the condition(s) detected, but allows the employee to request time off so that all 
employees with a referral letter can seek consultation4.  This latter form (without 
diagnosis, and only containing the case number) is to be signed by the provider and 
returned to the employer as evidence that the employee did seek medical consultation.   
 
1.4. New Start Centres 
IntraHealth International is a USA based company working in Namibia under PEPFAR 
(through USAID) supporting a network of 18 VCT centres across Namibia, under the New 
Start franchise. It incorporates all three models of service delivery, namely; free 
standing/stand alone, integrated, and mobile/outreach.  
 
Freestanding/standalone sites provide VCT services from a permanent site not connected 
with a health facility. These sites are dedicated to providing VCT services, with 
supplementary screening for alcohol abuse, TB and STI’s and referral of HIV positive 
pregnant women for PTMCT. These twelve free standing sites make referrals for follow up 
care at the appropriate public health facility. 
 
Integrated sites offer VCT services as part of an integral medical package from a health 
facility such as a hospital or health centre. Six such sites are located at health facilities in 
Andara, Nyangana, Oshikuku, Rehoboth St. Mary’s Hospital, Onandjokwe and Odibo.   
 
Some New Start Centres provide mobile outreach services, using tents or available 
community structures for the counselling rooms. However, at the moment the outreach 
operations are limited and no separate costs are reported for this.  
 
                                                     
4
 A system has been put in place where the employers are requested to return the form that has been signed by 
the health provider to NABCOA, so that Bophelo! can estimate follow up rates. However, at the time of 
writing this system is not yet fully operational. 
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All centres follow the same protocol: clients first receive pre-test counselling after which 
the test takes place. They then return to the waiting room and receive their results in 
around 20 minutes, followed by post-test counselling. If the client is HIV positive, a 
referral form to the local hospital is provided. As with Bophelo!, New Start’s service is 
anonymous and confidential – data is collected, but only on an anonymous basis.  
 
Many New Start Centres work in partnership with faith-based or community 
organisations, and all report to IntraHealth.  IntraHealth is responsible for the overall 
operation of all New Start Centres, data collection and funding (provided through a USAID 
contract).  
 
1.5. Study sponsorship 
This study was supported with funds from USAID Associate Award GHO-A-00-08-00001-00 
under Leader GHS-A-00-03-0020-00. The funding was awarded by the USAID Office of 
HIV/AIDS for the development and/or evaluation of public private partnerships for the 
prevention and treatment of HIV/AIDS. 
 
1.6. Study participants 
The following participants have been involved in this study: 
 
Boston University School of Public Health, Department of International Health, Center for 
Global Health and Development 
Boston University provided overall leadership and responsibility for the design and 
implementation of the research. 
 
PharmAccess Foundation Namibia 
As a key partner in the Bophelo! partnership responsible for the operations of the mobile 
clinics, PharmAccess Foundation Namibia provided the following data: 
- key data on all people tested, such as number of people tested positive and if they 
have ever tested for HIV before 
- demographic data on all people tested 
- operational cost information  
- funds received from employers and donors 
In addition, under a subcontract with Boston University, PharmAccess retained a costing 
expert to extract the financial data from all Bophelo! partners and New Start. 
 
NABCOA 
The Namibia Business Coalition on Aids (NABCOA) is one of the Bophelo! partners. 
NABCOA provided information on their costs incurred for part of the operations (one of 
the mobile clinics is owned by NABCOA) as well NABCOA’s outreach and marketing 
activities to encourage the use of Bophelo!. 
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NIP 
The Namibia Institute of Pathology (NIP) is also a Bophelo! partner. NIP provided 
information on the costs for the quality assurance services and certain incidental support 
supplied to Bophelo!.5 
 
 
IntraHealth - New Start Centres 
IntraHealth is responsible for the running of the New Start Centres in Namibia. IntraHealth 
provided the following information 
- key data on the number of persons tested 
- operational cost information 
- data on follow up tests for negative patients who may be in a “window period” 
after a recent risk of infection. 
- data on male/female ratio of people tested 
Data on the costs of marketing and promotion of the New Start Centres was provided by 
Nawa Life.  Data on the costs of test kits and other consumables associated with the test 
kits was provided by Supply Chain Management System (SCMS). Both Nawa Life and SCMS 
are prime partners of USAID and provide services directly to IntraHealth, funded through 
USAID. 
 
1.7. Approvals 
The following institutions have provided approval for this study: 
- Institutional Review Board, Boston University Medical Center 
- Ministry of Health and Social Services, Namibia  
Copies of the provided approvals are included in Appendix Two and Three.  
 
 
 
 
                                                     
5
 NIP currently supplies secure parking for Bophelo! vehicles. 
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2. Approach 
2.1. Introduction 
The study was designed by Boston University School of Public Health, in cooperation with 
PharmAccess Foundation Namibia. The draft study design was shared for comments with 
the Bophelo! partners, the Ministry of Health and Social Services in Namibia, IntraHealth 
and USAID.  
 
2.2. Data collection 
 
Timing 
All data regarding New Start included in this evaluation, both cost data and data on 
number of people tested, relates to the running of the New Start Operation from January 
2009 until December 2009.  
 
All data regarding Bophelo! included in this evaluation, both cost data and data on 
number of people tested, relates to the running of the New Start Operation from March 
2009 until December 2009. This time period was chosen because the project was not in 
full operation in January and February; not all staff had been hired and only pilot testing 
took place. 
 
Costs for management and staffing in previous years associated with planning and setting 
up the Bophelo! or New Start programmes have not been included.  The physical 
collection of data was performed from February 2010 to May 2010.  
 
Costing approach 
The underlying principle of this study is to obtain and allocate the full direct cost of all 
resources actually used by the Bophelo! and New Start programs in 2009. This includes 
depreciation of capital investment and the market value of any services or goods that 
were provided for free by any of the donors or Bophelo! partners. However, it does not 
include the costs of preparation and planning in previous years. 
 
Data sources 
Data was collected through the following sources: 
 
- PharmAccess Foundation )PAF): 
o General ledger: PAF tracks all expenses for the Bophelo! project. 
o Overview of all salaries (including overtime) paid to Bophelo! staff. 
o Log books of vans containing the number of kilometres driven in 2009 
o Petty cash register  
o Overview of all invoices to PAF  
o Overview of all overhead costs 
o Overview of funds received from NABCOA for Bophelo! 
o Invoices supplied to companies and overview of received payments 
o Discussions with Bophelo! operations manager and PAF accountant 
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- NABCOA: 
o General ledger: NABCOA tracks all expenses of the Bophelo! Project 
o Discussions with NABCOA accountant, dedicated Bophelo! staff member 
and NABCOA general manager. 
-  Namibia Institute of Pathology 
o Discussions with NIP staff: Manager Quality Assurance, Manager Corporate 
Affairs and medical and laboratory technicians 
o Overview of costs provided by NIP 
- IntraHealth 
o Financial data  provided by the Financial Director of IntraHealth on New 
Start staffing, operations and other costs 
o Data on the number of people tested and male/female ratio provided by 
the Technical Director of IntraHealth 
o Discussions with IntraHealth staff: Financial Director, Technical Director. 
- Supply Chain Management System (SCMS) 
o SCMS provides the test kits to the New Start Centres and is paid directly by 
USAID. SCMS provided an overview of the costs and quantities of all goods 
supplied to IntraHealth during the time October 2008 until September 
2009. Although this is a different time period to the study, SCMS assumed 
that the same amount of test kits would have been used from January 2009 
until December 2009.  
- Nawa Life 
o NAWA life provides the marketing activities for the New Start Centres and 
is paid directly by USAID. Nawa Life provided an overview of all their 
activities and costs related to the New Start Centres for January 2009 until 
December 2009. 
 
2.3. Cost categories and assumptions 
 
General 
 
Exchange rate 
The average exchange rate of the US dollar and the Namibian dollar for 2009 has been 
used: 1 US dollar = 8.43 Namibian dollars. To calculate this average, the historical data on 
exchange rates held by the South African Reserve Bank was used.6 
 
VAT 
All amounts in this evaluation are exclusive of VAT7, except where VAT would not be 
claimed back. This is for example the case for some PharmAccess expenses, such as dry 
cleaning and accommodation8. In addition, for the New Start Centres it was assumed that 
only 10.0% of all VAT paid was actually claimed back during 2009. 
 
                                                     
6
 See http://www.reservebank.co.za/. The South African Reserve Bank collects data on historical exchange 
rates against the South African Rand. As the Namibian dollar is pegged to the SA Rand, the same exchange 
rate has been used. 
7
 VAT in Namibia is 15.0%.  
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Operations  
 
Personnel cost 
Personnel costs are included according to the percentage of time spent on Bophelo! or 
New Start activities. For Bophelo!, we assumed that the coverage of additional diseases 
required more time for training, reporting, project management and senior management 
than in the situation where Bophelo! would have only tested for HIV. The assumption is 
that if Bophelo! had only tested for HIV, all staff time (excluding driver’s staff time) and 
training expenses would be 15.0% less than the reported costs for the overall screening 
programme. 
 
Travel and per diem cost 
Travel and per diem cost have been obtained directly from the relevant organisations, 
with the exception of the travel and per diem costs for the quality control checks for the 
New Start Centres. The cost for these visits was calculated using the distance of the 
centres to Windhoek, with the assumption that staff would travel maximum 800 
kilometres per day and would receive N$ 150.00 / US$ 17.81 per day as a daily allowance. 
 
Accommodation costs 
Wherever possible, the real costs spent on accommodation have been obtained directly 
from the relevant organisations. For NIP staff making quality control checks, an average 
cost of N$ 450.00 / US$ 53.00 has been assumed per night of accommodation. The 
number of nights is based on the maximum travel time of 800km per day and an 
inspection lasting around 5 hours per site. 
 
Maintenance cost for mobile clinics 
For the mobile clinic owned by PharmAccess, the real maintenance costs were included, 
which exceeded the maintenance provision. For the mobile clinic owned by NABCOA, the 
provision was included, as no maintenance costs have been incurred. As these 
maintenance costs will be incurred shortly, it was agreed to use as a cost the maintenance 
provision set up by NABCOA9. 
 
Maintenance costs of buildings owned by the New Start Centres 
The assumption is that the maintenance for the buildings of all New Start Centres has 
been included in the overall operational costs. 
 
Test kits  
For Bophelo!, the average cost of test kits has been obtained through a review of the 
invoices for test kits in 2009. The rate per HIV test kit including consumables for Bophelo! 
is N$ 46.74 / US$ 5.55. For New Start, the standard rate was N$ 28.09 / US$ 3.33, 
including consumables, as reported by their procurement agency, SCMS. The overall costs 
of the test kits was obtained by multiplying the cost of a test kit for each organisation by 
the number of people tested, and including a contingency for wastage of 10%. 
 
 
 
                                                     
9
 NABCOA makes a maintenance provision of N$ 3,000 a month, around US$ 356 per month. 
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Secure parking 
Currently, secure parking for the two mobile clinics is provided free of charge by NIP. Due 
to the limited offering of secure parking for medium sized vans, no quotations for secure 
parking for mobile clinics were available. However, cost information was obtained on the 
cost of secure parking near PharmAccess’ office. The assumption made is that parking 
would be three times the cost of parking a normal car in a secure parking area. 
 
Depreciation of mobile clinics 
It is assumed that the Bophelo! vehicles have a life span of five years, with zero salvage 
value. The initial investment of transforming the vans into mobile clinics has been 
included in the capital cost of the vans.  
 
Some New Start Centres own multiple vehicles, whereas other New Start Centres use cars 
of other organisations and incur a usage charge which is included in the operational costs 
reported in this study. All cars that are owned by the centres are older than five years and 
have been fully depreciated. Therefore, no cost for depreciation of these cars has been 
included. 
 
Depreciation – New Start Centres 
Where New Start pays rent, this is taken as the annual cost of occupying the New Start 
Centre.  Eight of the 18 New Start Centres currently do not pay rent, as the organisations 
hosting these New Start Centres own the buildings.  We therefore estimate depreciation 
to develop the annual occupancy cost for these eight sites. Depreciation for each facility 
was calculated on the basis of an average surface space of 300 square m2 and four gravel 
parking spaces of 10M2. Using an average building rate of N$ 4,800 / US$ 570 per M210, 
the assumed build cost is N$ 1,476,400 / US$ 175,156.49 per centre. Furthermore, a life 
span of 40 years was assumed, with zero salvage value. We assume that each centre is 
equipped with standard furniture (approx. 20 chairs, 5 desks, 2 tables) for N$ 28,500 / US$ 
3,381.17 with a life span of 8 years with zero salvage value. In addition, the assumption 
has been made that each centre owns office IT equipment consisting of four computers, 
one copier, one printer, one fax and four phones. In total it has been assumed that the 
value of this would be N$ 46,000 / US$ 5,457.33 with a life span of 3 years and nil salvage 
value. 
 
Overhead 
For each organisation, the overhead charge was dealt with differently. For PharmAccess, 
the real overhead was included, based on a PharmAccess overview of all overhead costs 
of 2009. For NABCOA, the organization’s standard overhead charge of 10% was included. 
For both these organisations the management time spent on the projects has been 
included separately, and is thus not included in the overhead charge. For NIP an overhead 
charge of 30% was calculated on the costs included11 as the NIP cost overview excludes 
charge for management time12, except for the time spent directly on meetings. 
                                                     
10
 Based on data from Jordaan Oosthuysen Nangolo, a local construction engineering company. This rate 
includes allowances for carpets, wallpaper, lighting and air-conditioning. 
11
 With the exception of test tariffs, as these already include cover for overhead 
12
 Although NIP cost data includes the time of management spent on meetings for the Bophelo! partnership, 
no other management time has been included for the overall running of their organisation.  
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IntraHealth reported a standard overhead charge under its USAID contracts of 30.89%.  
No overhead was calculated for Nawa Life (responsible for promotion) and SCMS 
(procurer of test kits) as their rates already include overhead charges. 
 
Management time – Bophelo! partnership 
Each partner organisation was requested to provide an estimate of the time that 
management was involved in the operation of Bophelo!. It was assumed that at a 
minimum, management would attend monthly meetings of 2 hours, with 1 hour follow up 
and preparation.  
 
Marketing 
For Bophelo!, the costs of marketing have been included as collected through NABCOA 
and PharmAccess. The costs associated with the launch of the Bophelo! programme in 
March have been excluded, as this cost is considered as part of the preparation of the 
programme13. For IntraHealth, all marketing activities are performed by Nawa Life, which 
provided the cost data on their activities. 
 
Outreach operations New Start Centres 
Several New Start Centres operate outreach services on an ad hoc basis. IntraHealth 
reports that the outreach operations are minimal and incremental costs of moving staff 
offsite for such sessions are negligible. In addition, it was not possible to separate the 
costs or number of people tested during outreach visits. 
 
Contributions to New Start Centres from other donors  
Many New Start Centres work together with faith-based or community organisations. 
IntraHealth provides the funding for the operation of the testing centres, but is aware that 
in some cases other organisations donate time, money or goods to the New Start Centres. 
We assume that the value of this contribution represents 5% on top of the operational 
costs reported by IntraHealth. 
 
Quality Control 
Quality control for both mobile and fixed site screening is performed by the Namibia 
Institute of Pathology. As no recent invoices are available, we agreed with NIP to use its 
tariffs for standard tests/activities where available and to work out the cost price where 
tariffs are not available14. 
 
Preparation of tests and executing tests 
Where NIP publishes a tariff for a test, this tariff has been used, with a discount of 20%, 
similar to that granted by NIP to large customers such as MOHSS. Where no tariff was 
available, an assumption was made based on discussions with the NIP technicians and 
management regarding time and consumables required. Standard salary scales supplied 
by NIP for technicians and management were used. 
 
                                                     
13
 The costs of the launch constitute 1.6% of the overall costs. If these costs are included the cost per person 
tested for HIV is US $1.21 higher than if these costs are excluded.  
14
 Under the  Memorandum of Understanding, NIP provides its services for free to Bophelo! Furthermore, 
IntraHealth noted that they have not received an invoice for the past two years. 
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On site inspection 
An on-site inspection is required for the initial certification, and annually thereafter for the 
re-certification every two years. It has been assumed that this takes five hours for the two 
mobile clinics, and similarly five hours for each New Start Centre.  
 
Quality control by Council of Churches in Namibia (CCN) 
IntraHealth reported that part of their quality control is done by CCN instead of NIP. As no 
cost estimates have been provided for this service, the assumption has been made that 
the costs would be similar to a situation where NIP would provide full quality assurance.  
 
Data on people tested 
 
Bophelo!  
Data on Bophelo! was collected through PharmAccess’ database on all people tested 
during 2009. This anonymous database includes full information on: 
 the number of people tested,  
 the number of people testing positive for various condition,  
 the number of people who stated that they are already HIV positive,  
 the number of people stating that are already on ART  
 the number of people who had tested for HIV before.  
In addition, this database holds information on the demographics of the people tested. All 
data is collected anonymously and no identifiers are included in the database. 
 
New Start data 
Data on the New Start Centres was collected through New Start’s head office, which 
provided: 
 the total number of people tested per centre,  
 the number of people tested positive per centre and  
 the number of people that returned for re-testing within the 3-month 
window period.  
The data includes the people tested during the National Testing week.  
 
Client company contributions 
All company payments for Bophelo! services are based on the amounts paid to 
PharmAccess for services delivered from March until December 2009 for HIV testing – any 
amounts paid specifically for wellness testing (for conditions other than HIV) have been 
excluded. Although PharmAccess charges VAT to the companies, for the purpose of this 
study VAT has been excluded from the company contributions as the companies would be 
able to claim the VAT contribution back from the Ministry of Finance.15 
 
2.4. Data analysis 
Before data was analysed, quality control checks were performed on the data: 
                                                     
15
 PharmAccess will charge and collect VAT on the fees charged for its services. PharmAccess will pay VAT 
on the services that it buys. The net difference between the collected VAT and paid VAT is paid to the 
Revenue Authority or claimed back from the Revenue Authority at the end of each tax period.  
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- Comparison of gathered data with available cost data. For example the expenses 
on fuel were compared with the kilometres noted in the logbooks multiplied by 
the current fuel charge, and the costs of NABCOA and PharmAccess were 
compared to note any omissions or discrepancies. 
- Following on from this, further checks were done on items that appeared 
inconsistent. For example, invoices were compared with items booked in the 
PharmAccess’ general ledger for Bophelo!.  
- A sensitivity analysis has been done on the separate cost categories. This showed 
that for Bophelo! there are three cost categories that together account for more 
than half of the total costs. 
 
After the quality control check, the Bophelo! data was split into different time periods: 
- From January through October, and for November and December. In the last two 
months of 2009, Bophelo! mainly tested rural communities. With the high costs of 
travel and accommodation in the latter period, we expected the cost per person 
tested to be higher.  
- For January and February, and from March through December. The Bophelo! 
operation only reached full speed in March, so unit costs may have been higher in 
the earlier start up period.  
 
Subsequently, the data was analysed using an Excel model (Appendix Five) specifically 
designed for this purpose. Using this model, an overview was made of the different cost 
categories and their relative importance to the overall costing. In addition, the model 
provides an overview of the unit cost for a range of alternative output measures: such as 
the cost per person screened for HIV and the cost per newly identified HIV infected 
person. 
 
2.5. Existing literature on VCT unit costs 
No information was found regarding the unit costs of mobile HIV testing clinics that also 
include screening for other diseases, but several studies provide information regarding the 
unit costs of VCT. However, as recognised by Walker (2003) and McConnel et al (2005), 
the comparability of the existing data is questionable, as estimates vary wildly. For 
example, unit cost estimated varied between US$ 1.50 in Russia in 2003/2004 (Marseille 
et al, 2007), an average of US$ 10.60 in 2005 comparing 60 studies (Schwartlander et al, 
2005), to averages of US$ 26.65 in Kenya (1995 – 1998), US$ 28.93 in Tanzania (1995 – 
1998) (Sweat et al, 2000), to US$ 47.34 in 1999 In Kenya (Forsythe et al, 2002) and US$ 
101.58 per client in South Africa in 2003 (McConnel et al, 2005).  
 
There is some recent information available on the costs of fixed site and mobile VCT.  
Menzies et al (2009), working in Uganda, compared the unit costs in a period between 
2003 and 2005 for four methods of HIV testing, including hospital based testing and 
testing of household members of HIV positive cases.  Stand alone fixed site VCT cost 
$19.26 per person tested and $100.59 per HIV-positive individual identified.  Door to door 
VCT was less expensive per person tested ($8.29), but more expensive for each HIV 
positive client identified ($163.93).   In Kenya, Grabbe and colleagues (2009) found that 
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the unit cost of mobile testing16 in 2005-2006 averaged $14.40 per client tested; $151.62 
per HIV positive, and $177.23 for each newly identified positive case.    In the same study, 
stand alone fixed site VCT clinics cost $23.62 per client, $171.07 per HIV positive client, 
and $474.68 per newly identified HIV positive17. 
 
Using inflation data on average consumer prices1819, the units costs reported in the 
literature would represent the following unit costs in 2009: 
 
 
Table 2: Historical unit cost data per HIV test 
 
Year of 
research 
Time 
period 
considered 
Number of 
people 
tested 
Unit cost in 
year of 
research (US$) 
Unit cost in 
2009 (US$) 
Russia 2003/2004 NA NA 1.50 2.86 
India 2005/2006 1 year 66,445 3.33 4.17 
Average of 60 studies 2005 NA NA 10.60 12.41 
Tanzania 1995 - 1998 1 year ***601 28.93 58.41 
South Africa** 2003 1 year 662 53.02 66.84 
Kenya 1995 - 1998 1 year ***716 26.65 71.91 
Kenya 1999 2 months 423 47.34 120.74 
Kenya (mobile) 2005-2006 1 year 45,539 14.40 15.32 
Kenya (fixed site) 2005-2006 I year 14,634 23.62 25.13 
South Africa* 2003 1 year 662 101.58 128.06 
Uganda (fixed site) 2003-2005 
6-12 
months 
9,604 
19.26 21.87 
Uganda (door to door) 2003-2005 
6-12 
months 
49,470 
8.29 9.41 
*    average of study period 
**  last quarter of study period 
***This is the number of participants. However, the study also states that the costs are based on a free-
standing clinic with capacity to process 3,000 clients per year (Sweat et al, 2000).  
 
It is clear from this table that the range of reported unit costs is very broad.  Costs for test 
kits have fallen over the period since 1990, but wages will have risen. . The amount of 
time considered adequate for counselling will have cultural variations (and may explain 
the low cost in Russia).  Unit costs are clearly sensitive to the volume of the program, the 
location of the testing sites, and the willingness to be tested. 
 
Certain cost studies provide a break down into different categories, which all reveal the 
same structure: staff costs usually constitute by far the largest amount, followed by costs 
                                                     
16
 Some mobile testing was done in mobile containers similar to Bophelo!  that were moved from site to site 
and left for periods of a week or two; in others, a team of testers moved from site to site without dedicated 
clinics. 
17
 The authors speculate that this may be because of a significant number of “repeat” testers at stand alone 
VCT sites. 
18
 IMF, www.imf.org 
19
 For India and South Africa the costs were calculated back to the original local currency equivalent. 
Subsequently, CPI inflation figures were used to calculate the unit cost in 2009, and then transferred to US 
dollar using the average 2009 US exchange rate. For the other countries the foreign exchange fluctuations 
were not included in the calculations. 
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of recurrent goods, such as HIV test kits. See the table below, which provides an outline of 
five studies. 
 
 
Table 3: Cost categories in previous studies 
Study Country Staff as % of total 
cost 
Recurrent goods as 
% of total costs 
Dandona et al, 2008 India 47% 37% 
McConnel et al, 2005 South Africa 80% 20% 
Sweat et al, 2000 Kenya 49% 25% 
Sweat et al, 2000 Tanzania 55% 24% 
Forsythe et al, 2002 Kenya 59% 38% 
 
2.6. Limitations 
Information on the Bophelo! programme was readily available and in a clear format, with 
the researcher having free access to all cost data and all data collected during 2009 on 
Bophelo! clients. Relatively few assumptions were necessary; parking of the Bophelo! 
vans, quality control activities and the useful life and salvage value of the vans were the 
few exceptions.  Of these, only the depreciation assumption accounts for more than 1% of 
the total costs of the Bophelo! operation. 
 
As many New Start Centres are run by other organisations, New Start does not have a 
complete overview of the goods and services that these organisations provide to the New 
Start Centres. Although 5.0% was added on top of the operation costs to allow for 
contributions by other organisations, it is difficult to judge the accuracy of this figure 
without researching every centre, which is outside of the scope of this research.  
 
In addition, it was not possible to segregate IntraHealth’s costing for more specific 
categories; ‘other operational costs’ provided was 15.3% of all IntraHealth costs. This has 
limited the researcher’s ability to investigate the different items included in this category 
and spot any omissions or discrepancies.  
 
As detailed above, assumptions were made for New Start with regard to the depreciation 
of existing buildings, vehicles, furniture and equipment, totalling 9.2% of all costs.  
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3. Costs of mobile HIV/AIDS screening in Namibia 
3.1. Introduction 
Currently, the Bophelo! clinics are the only mobile clinics in Namibia that specifically 
target companies and their employees for testing on HIV/AIDS and other diseases. This 
chapter will outline the results and the costs of the activities in 2009. 
 
3.2. Number of people screened and prevalence 
 
From March through December 2009, 5,734 clients were screened in the Bophelo! clinics 
for a range of diseases. Of the total number of clients, 10.6% refused to undertake a HIV 
test20, leading to a total of 5,124 clients tested for HIV, as illustrated in Table 4. The 
population tested shows a prevalence of 10.5% compared to an estimated HIV prevalence 
of 13.3% among adults in Namibia.21 However, some of those who declined the HIV test 
but took the other screening tests likely knew they were HIV positive, so the HIV rate in 
the total population screened could be somewhat higher than shown here. 
 
Table 4: Number of people screened in March - December 2009 (Bophelo!) 
  
Number of 
people 
As % of total number of 
people tested 
Number of people screened 5,734 100.0% 
Number of people tested for HIV 5,124 89.4% 
Number of people tested for HIV for the 
first time 1,182 23.1% 
Number of people tested positive 537 10.5% 
Number of people tested positive for the 
first time 421 8.2% 
 
In total 10 organisations from the agricultural, services, utilities, multi-industry and 
transport sectors were screened, as indicated in Table 5 below. It should be noted that the 
third agricultural organisation listed represents an agricultural union, consisting of 
multiple smaller farmers. The agricultural organisations were tested in the last two 
months of 2009, when the mobile clinics were used for a rural pilot. 
                                                     
20
 Reasons provided for not undertaking a test were: not ready (49%), already knows status (44%), HIV 
positive (7%). 
21
Estimated adult HIV prevalence derived from the UNAIDS Spectrum Model, see HIV and AIDS 
Partnership Framework 2011 – 2016, 2010 
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Table 5: Overview of sectors and company size 
Company Industry 
Number of people 
tested 
Size of company 
1 Agriculture 72 50 – 100 
2 Agriculture 24 10 – 50 
3 Agriculture 372 0 – 10 
4 Multi-industry 3363 >2000 
5 Services* 35 50 – 100 
6 Transport 111 1500 – 2000 
7 Transport 268 250 – 500 
8 Transport 225 250 – 500 
9 Utilities 747 500 – 1000 
10 Utilities 517 500 – 1000 
 Total 5,734 
 
*this particular company agreed to participate as a pilot with a limited number of people. 
 
The locations where testing took place are spread out over Namibia. The map below 
provides an overview of all locations where the Bophelo! clinics have provided wellness 
testing during March until December 2009. 
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Figure 1: Map of testing locations (Bophelo!) 
 
3.3. Demographics 
Bophelo! focuses on testing at the workplace. Hence, the people tested are employed.22 
Of these employees, 75.2% classified themselves as labour, as indicated in the table 
below23.  
 
Table 6: Employment levels 
  Frequency Percent 
Management 358 6.4% 
Supervisor 423 7.6% 
Administration 604 10.8% 
Labour 4,194 75.2% 
Total 5,579 100.0% 
 
Of the total population tested from March to December 2009, 64.2% were men and 36.0% 
women, with 55.0% between the age of 25 and 3924. 
                                                     
22
 Only the dependents of the farm employees that were tested in the rural pilot in the end of the 2009 are 
unemployed. If one assumes that the total number of dependents is half of the number of people tested during 
the rural pilot, the number of unemployed would constitute less than 4% of the total population tested. 
23
 This data was only available for 5,579 clients, representing 97.3% of the population tested for wellness 
screening from March to December 2009. 
 24 
 
Table 7: Age/sex distribution of people testing at Bophelo! 
Age 
category 
Number of 
males tested 
% of total 
population 
Number of 
females tested 
% of total 
population 
Total age 
group 
< 25 431 7.5% 319 5.6% 14.0% 
25 – 29 674 11.8% 449 7.8% 20.0% 
30 – 34 651 11.4% 446 7.8% 19.0% 
35 – 39 574 10.0% 362 6.3% 16.0% 
40 – 44 448 7.8% 223 3.9% 12.0% 
45 – 49 368 6.4% 136 2.4% 9.0% 
50+ 528 9.2% 117 2.0% 11.0% 
Totals 3674 64.2% 2052 36.0% 100.0% 
 
3.4. Prevalence of all diseases 
The Bophelo! clinics also screen for eight other diseases or risk factors. The data collected 
indicates that 50.6% of all people tested positive for one or more conditions while 49.4% 
had none of the conditions tested.  36.6% people had one condition and 14.0% had two or 
more conditions. 
 
3.5. Bophelo! costing overview 
 
Overview of costs of running mobile clinics – HIV testing only 
The total cost of the Bophelo! programme from March until December 2009 was N$ 2.6 
mln / US$ 310,337. This is the full cost of running the two mobile clinics from March until 
December, testing 5,124 people for HIV, and excludes the costs associated with screening 
for the other eight diseases/conditions.  The table below shows the breakdown of the 
costs. 
 
Table 8: Cost categories 
Category Total cost(N$) Total cost (US$) % of total cost 
Operations 2,103,409 249,543 80.4% 
Programme 
management 248,790 29,516 9.5% 
Marketing 248,252 29,452 9.5% 
Quality control 16,353 1,940 0.6% 
Total 2,616,805 310,451 100.0% 
 
 
If the data is broken down into more specific categories, it is evident that more than half25 
of the costs of the Bophelo! operation originates in just three categories: van-related 
                                                                                                                                                                 
24
 Data on demographic was only available for 5,726 clients, representing 99.9% of the population tested for 
wellness screening from March to December 2009. 
25
 55.6% of costs originate in the categories „van-related costs‟, „staff cost‟ and „S&T‟. 
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costs, staff costs and costs associated with subsistence and travel. See also the pie chart 
below. 
 
Figure 2: Cost categories 
 
 
The categories include the following costs: 
 
Vehicle related costs: 19.5% 
These are costs associated with the mobile units : depreciation, fuel, maintenance costs, 
insurance and the salaries of the drivers. 
 
Staff cost: 19.2% 
Staff time of people operating the mobile clinics: the wellness testers, the counsellors and 
the supervisors. This category does not include time of senior or programme 
management, or the salaries of the drivers. 
 
S&T  (Subsistence & Travel): 16.9% 
This includes accommodation, daily allowances and travel costs for staff. 
 
Test kits: 11.0% 
This cost of test kits also includes the cost of associated consumables, such as gloves and 
cotton wool.  
 
Programme management: 9.5% 
Programme management includes the cost for a full time programme manager. 
Furthermore, it includes bank charges, legal costs, interest received, office costs such as 
copying (so far as these have not been included in overhead) and dry cleaning. In addition, 
the personnel costs of data collection and analysis have been captured in this category. 
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Marketing: 9.5% 
Marketing includes the costs of NABCOA’s outreach activities, the cost of producing 
marketing materials, such as leaflets and brochures.  
 
Management time: 7.9% 
This includes the time spent by senior management of each of the three Bophelo! 
partners. 
 
Overhead: 5.9% 
Overhead includes all overheads of the Bophelo! project, but does not include 
management time, as this is accounted for separately. 
 
Quality control: 0.6% 
Quality control includes the annual inspection and bi-annual certification of the mobile 
clinics and the quality assurance panels that are performed by NIP during the year. 
 
Overview of costs per person tested 
The table below shows the cost per person tested. This data only includes the cost of HIV 
testing and excludes the costs of the wellness tests. The average cost of screening one 
person for HIV in the Bophelo! mobile clinics during March--December 2009 was N$ 
510.70 / US$ 60.59. 
 
Table 9: Unit costs Bophelo! 
 Average cost for March – Dec 2009 Cost (N$) Cost (US$) 
Cost per patient screened for HIV* 510.70 60.59 
Total cost divided by the number of patients 
screened for the first time for HIV* 2,213.88 262.65 
Total cost divided by the number of patients 
identified as HIV positive 4,873.01 578.12 
Total costs divided by the number of patients 
newly identified as HIV positive 6,215.69 737.41 
* excluding clients who refused HIV testing and this excludes any costs of non-HIV wellness tests 
 
Cost variation during the year 
The costs were separated into the following different time frames: 
- January – October and November - December. In the last two months of 2009, 
Bophelo! mainly tested rural communities.  Due to the high costs of travel and 
accommodation, the cost per person tested was expected to be higher in the later 
period.  
- January – February and March - December. The Bophelo! operation only started in 
full in March after the official launch. 
 
When considering the different time frames, the unit cost per person tested varies 
substantially, as illustrated in the chart below.  
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Figure 3: Overview of unit costs during 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following table provides more detail on the cost variation during the year, and the 
total costs divided by the number of patients screened for the first time, the number of 
patients identified as HIV positive26 and the number of people newly identified as HIV 
positive. 
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 This includes people who are already aware of their positive status, but still want to undertake the HIV test. 
In November and December 
mainly rural communities 
were tested, with higher travel 
and S&T cost 
In January and February the 
Bophelo! programme had not 
been officially launched and was 
only functioning as a pilot 
scheme, testing a small number 
of people 
From March until 
December the Bophelo! 
operation was fully 
operational 
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Table 10: Overview of unit costs during 2009 
  
Jan – Oct 
(US$) 
Nov – Dec 
(US$) 
Jan – Feb 
(US$) 
March – 
Dec 
(US$) 
2009 
Average 
(US$) 
Cost per patient 
screened for HIV* 61.61 72.37 125.83 60.59 63.24 
Total cost divided 
by the number of 
patients screened 
for the first time 
for HIV* 313.72 165.85 447.61 262.65 271.73 
Total cost divided 
by the number of 
patients identified 
as HIV positive 575.69 959.78 3,033.83 578.12 618.60 
Total costs divided 
by the number of 
patients newly 
identified as HIV 
positive 748.55 1,219.72 NA 737.41 802.27 
* excluding clients who refused HIV testing  
 
Due to the nature of the pilot in the rural areas of Namibia during November and 
December, the unit cost of testing one person for HIV is higher than during the rest of the 
year. The increase is 14.4% compared to the average of 2009 and 19.4% when compared 
to the cost when the clinics were fully operational. In addition, due to the fact that the 
Bophelo! operation only fully started in March, the cost of testing one person for HIV 
during January and February 2009 (US$ 125.83) is substantially higher than the 2009 
average of US$ 63.2427 or the cost when the Bophelo! operation was fully operational, 
which was US $ 60.59.  
 
When looking at cost per patient screened for the first time, a different outcome is clear: 
the cost per patient screened for the first time in November and December, when the 
rural pilot took place, is 38.9% lower than the annual average. Although the costs per 
person in this time period were higher, largely due to the longer distances travelled, a 
larger proportion of first-time testers was reached.    
 
With respect to the cost per patient identified as HIV positive, there is a large variation 
between the short time periods (November to December and January to February) and 
the longer time periods (January to October and March to December). This likely occurred 
because of the higher costs per person tested and a lower HIV prevalence both in the rural 
communities and the companies tested in the first two months of 2009. 
 
The period from March until December most accurately reflects the ongoing operations of 
Bophelo!: during this period full time staff was hired (not the case during January and 
                                                     
27
 The cost of one person tested during January and February was 99.0% higher than the 2009 average. 
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February). To provide a representative reflection of the cost of Bophelo! in an ongoing 
situation, the remainder of this report will consider the costs from March until December. 
 
Opportunities for cost savings  
As 2009 was the first year of operation, it is likely that the clinics could be used more 
efficiently in future years. Per day, the two Bophelo! clinics could test 64 people 
maximum28. If one would assume that the mobile clinics would be operational for 50 
weeks a year29, and 15.0% lag/travel time, then 13,600 people could be tested. In that 
case, the per patient cost could be lowered to N$ 306.52 / US $ 36.3630 if a whole year is 
considered. This difference is caused by the fact that fixed costs, including staff costs, are 
paid even if the van is not in use. If the lag/travel time is higher, for example 25.0%, then 
the costs could be lowered to N$ 328.00 / US$ 38.91 per person tested for HIV. 
 
Cost for full wellness testing 
Although this research focuses on the costs of HIV testing, the Bophelo! clinics found that 
50.6% of those tested had at least one condition of concern.  We can look at this cost in 
two ways.  We can divide the total cost of the Bophelo! program by the full number of 
people tested, including those who elected NOT to have the HIV test.  This adds an 
additional 510 persons tested.  Or we can estimate the labor and materials required to 
conduct the additional tests once a patient is receiving the HIV test and counselling.  
 
The following table applies the first approach and shows the cost per person tested for  
wellness screening for all who participated in the screening program from March to 
December 2009.  It also shows the cost per condition identified for the period.  This 
calculation includes the costs of the wellness screening tests, which were excluded from 
the previous tables. The cost of providing full wellness testing is N$ 552.03 / US$ 65.49 per 
person tested, based on all people that took part in the wellness testing (5,734).  The 
increase in costs per person screened is only US$4.23, with the larger number of people 
testing partially offsetting the cost of testing for the additional diseases. 
Table 11: Cost of providing wellness tests 
 Cost (N$) Cost (US$) 
Full operating cost of a mobile, multi disease 
screening program in Namibia 3,165,357 375,530 
Cost per patient screened*  552.03 65.49 
Cost per patient screened without HIV test ** 587.70 69.72 
Cost per condition identified 729.01 86.49 
Cost per person identified with one or more 
condition 1,049.22 124.48 
Percentage of people identified with one or more 
condition 50.6% 50.6% 
*including clients that refused HIV testing, but did undertake wellness testing 
**excluding clients that refused HIV testing 
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 Each van has two consulting rooms;  16 people maximum can be tested per consulting room per day. 
29
 Assumption that around Christmas and New Year the mobile clinics would not run for two weeks. 
30
 Calculated using proportionally increased van related costs (petrol and maintenance), additional costs of 
test kits, S&T (based on Nov/Dec 2009), accommodation (based on Nov/Dec 2009) and includes staff for one 
full year. 
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Looking at adding the screening costs for the other diseases to the HIV counselling/test, 
we get the incremental cost, which is higher than this cost difference.  
- cost of the wellness test kits for other diseases:  
o N$ 72.69 / US$ 8.6231 per person tested 
- extra staff time (15%): N$ 131,725 / US$ 15,627  
o N$ 22.97 / US$ 2.73 per person tested32 
Bophelo! staff estimated that the full battery of tests for a person taking the HIV test 
rarely took more than 15% longer that the HIV test alone, and might have been less.  The 
HIV test takes time to develop, during which other tests are conducted.  Post HIV test 
counselling cannot begin until the HIV test results are known.  So testing for other 
diseases is an efficient use of the time that patients wait for their HIV test result. 
  
The total incremental costs of providing wellness testing is N$ 95.67 / US$ 11.35. 
Compared to the average unit cost of testing one person for HIV only, this is an increase of 
18.7%, to screen for all the additional diseases  
 
 
3.6. Sensitivity analysis 
The following assumptions were tested: 
 
 
Useful life of the mobile clinics 
The current assumption is that the useful life of the mobile clinics is 5 years, with nil 
salvage value. If this would be shortened to 3 years, the overall costs would increase by 
2.4%, leading to an average per person tested price of N$ 522.86 / US$ 62.03. 
 
 
Number of people tested 
To provide for comparisons across different VCT modes, the per person unit cost has been 
calculated. Naturally, the unit cost is highly dependent on the number of people actually 
tested. In this case, the number of people tested is considered to be reliable, as patient 
data has been collected in all cases. However, if one would consider 20% less people or 
20% more people tested during March until December 2009, the per person unit costs 
would change respectively from + 17.5% to -11.6%. 
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 Including a provision for 10% wastage 
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 Based on all people that participated in wellness screening during March – December 2009, which is 5,734. 
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Table 12: Overview of unit costs with increase/decrease in number of people tested 
 
Difference in 
number of 
people tested 
Total number 
of people 
tested 
Per 
person 
cost N$ 
Per 
person 
cost US$ 
% change 
per unit cost 
20% less people 
tested -1,025 4,099 599.88 71.17 17.5% 
10% less people 
tested -512 4,612 550.33 65.29 7.8% 
actual number 
tested 0 5,124 510.70 60.59 0.0% 
10% more 
people tested 512 5,636 478.27 56.74 -6.4% 
20% more 
people tested 1,025 6,149 451.24 53.53 -11.6% 
 
This table includes the extra costs of test kits per person tested and proportional extra or 
less fuel and S&T costs. It does not include extra staff cost, as there is assumed to be spare 
capacity to provide the extra wellness tests. The results show that the per person costs 
decrease with an increase in scale, indicating an increased efficiency in line with the 
findings of the PANCEA project that researched the association between scale and 
efficiency for five countries (Marseille, 2007). 
 
Lower price of test kits 
Bophelo! did not procure test kits in bulk, and therefore pays a relatively high price of US$ 
5.55 per test kit33. If a lower price is used, for example that for New Start, the cost per 
person would decline to N$ 490.18 / US$ 58.1534. 
 
3.7. Sources of funding 
Funding for Bophelo! for the period of March until December 2009 originates from the 
following sources: 
 
- Domestic private sector: from March until December 2009 ten Namibian 
organisations requested the services of Bophelo!. Although the invoice approach 
differed per company, in general the companies were invoiced for separate 
categories of cost, such as the staff time, mobile unit costs (such as insurance and 
maintenance), accommodation, and kilometre charges. The invoice would outline 
each item and would clarify which items would be covered by subsidy from 
NABCOA (Global Fund). The company would pay the remaining items. The total 
amount that the private sector contributed during this time period to the HIV 
testing part of the Bophelo! programme is N$ 986,138 / US$ 116,993, over a third 
of all the costs of Bophelo!. This excludes any payments specifically made with 
regards to wellness testing (for non-HIV diseases and risk factors)35, which was N$ 
33,924 / US$ 4,025. 
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 IntraHealth buys its test kits on average for US$ 3.33 (excluding any calculation for wastage) 
34
 Including 10% allowance for wastage 
35
 If payments for wellness testing are included, the overall private contribution is N$ 1,020,062 / US$ 
121,018, 30% of all total costs for providing full wellness testing. 
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- Domestic public sector: the Namibia Institute of Pathology provides free quality 
control and free secure parking. The total value of NIP’s contribution for March 
until December 2009 is estimated at N$ 29,300 / US$ 3,476. 
 
- International donors: 
o For the period March until December 2009 the Global Fund through 
NABCOA has provided N$ 1,049,100 / US$ 124,463 as direct funding for 
salaries, test kits and KAPB surveys  
o The Global Fund provided the majority of the funding of NABCOA’s role in 
outreach and marketing, a total value of N$ 418,313 / US$ 49,62836 
o A range of other international donors has provided NABCOA’s management 
fee of N$ 120,000 / US$ 14,237. 
o The Dutch NGO HIVOS provided funding for testing of farmers of N$ 
11,850.00 / US$ 1,405.86 
o The PharmAccess Foundation has contributed N$ 2,103 / US$ 250 through 
their role as programme manager of Bophelo!. 
 
Overall, the graph below shows that the main funder of the costs of Bophelo! is the Global 
Fund, followed by the private sector contributions of 38% of the total costs. Looking at a 
local perspective, 39% was sourced from within Namibia. 
 
 
Figure 4: Overview of funding sources 
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 The costs of depreciation are also included as a Global Fund contribution: even though currently no 
depreciation is charged, Global Fund initially paid for NABCOA‟s van.  
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4. Fixed site screening in Namibia 
4.1. Introduction 
IntraHealth runs the 18 New Start Centres in Namibia. This chapter provides an overview 
of the cost data on these 18 centres. 
 
4.2. Prevalence 
70,143 people were tested in the 18 New Start Centres in Namibia in 2009. 16.0% of all 
people tested at New Start Centres in 2009 were tested during the National Testing Week.  
The overall prevalence among the population tested in 2009 is 10.5%, very similar to that 
observed by Bophelo!. The prevalence per centre differs widely from 4.8% to 19.6%.  
 
Of all people tested, 11.8% were so-called “re-testers”, people that had tested within the 
prior 12 months, either at New Start, or at other testing centres. The actual number of 
individuals that were reached through the New Start Centres during the year is 61,89537. 
 
4.3. Demographics 
New Start data shows that 57.1% of all people tested are women, and 42.9% are men. 
                                                     
37
 This counts people that might have tested twice as one person. 
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4.4 New Start costing overview 
 
Overview of costs of running 18 fixed site VCT centres 
 
Overall, the New Start Centres have reported costs of just over N$ 34 million, or about  
US$ 4 million. 
 
Table 13: Cost categories New Start Centres 
Category N$ US$ % of total cost 
Operations 30,553,830. 3,624,832 88.8% 
Programme management 1,920,000 227,784 5.6% 
Marketing 1,558,655 184,915 4.5% 
Quality control 382,725 45,406 1.1% 
Total 34,415,209 4,082,936 100.0% 
 
If the data is broken down into more specific categories, it becomes clear that the main 
cost category is staff costs, followed by overheads and other operational costs. See also 
the pie chart below. 
 
 Figure 5: Detailed cost categories New Start Centres 
 
Staff cost 35.8% 
Staff costs include the costs of all staff at the New Start Centre, as provided by 
IntraHealth. This excludes any staff that contribute to the New Start Centres that might be 
paid by other organisations38. 
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 In discussion with IntraHealth a 5% addition was included in the overall operating costs to allow for 
contributions made by other organisations. 
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Overhead 18.0% 
Overhead is 30.89% of direct costs, the approved indirect cost rated charged to USAID 
under the IntraHealth contract. 
 
Other operating costs 17.9% 
Other operating costs include rent, utilities, maintenance of cars and buildings, fuel and 
other operational costs that might occur. This data also includes an estimate of 5% to 
cover the contributions of other organisations to the New Start Centres that are not 
included in the USAID contract payments.  Unfortunately it was not possible to separate 
this data further. 
 
Building related costs and depreciation 9.2% 
This category consists of the depreciation on four buildings owned by New Start’s partners 
plus depreciation on IT equipment and furniture. 
 
Test kits 6.3% 
The costs for test kits also include the costs for consumables, such as needles, wool, etc. 
 
Programme management/management time 5.6% 
This category represents the cost of management time devoted to the New Start program 
by managers and staff at the central IntraHealth office in Windhoek. 
 
Marketing 4.5% 
Marketing costs include the allocation of salaries of Nawa Life employees, the costs of 
publication materials and other media channels, such as radio and TV.  
 
Travel 1.6% 
This includes the cost for travel as reported by IntraHealth. 
 
Quality control 1.1% 
Quality control includes the annual inspection and bi-annual certification of the clinics and 
the quality assurance panels that are performed by NIP during the year. It also includes 
petrol, S&T and accommodation for NIP staff performing quality control. 
 
Overview of costs per person tested 
The following table provides an overview of the costs per person screened for HIV. 
Because New Start did not collect data on those testing for the first time, or testing 
positive for the first time, costs in these categories cannot be calculated. The average 
across all New Start Centres in 2009 is N$ 490.72 / US$ 58.22. 
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Table 14: Unit costs New Start Centres 
 N$ US$ 
Total costs 34,415,209 4,082,936.33 
Cost per patient screened for HIV 490.64 58.21 
Total cost divided by the number of patients 
screened for the first time for HIV* NA NA 
Total cost divided by the number of patients 
identified as HIV positive 4,695.76 557.09 
Total costs divided by the number of 
patients newly identified as HIV positive NA NA 
Cost per person reached by New Start 556.03 65.97 
 
4.5  Sensitivity analysis 
The following assumptions were tested: 
Contribution by donors 
The assumption taken in the study is that the contribution from third party donors that 
provide resources to New Start without charge is 5.0%. However, if that would be changed 
to 10.0%, the total costs per person for New Start Centre would be N$ 503.18 / US$ 59.70 
per person, an increase of 2.6%. Similarly, if the contribution from third parties is 
estimated to be 20.0%, the costs per person would increase to N$ 528.26 / US$ 62.67, an 
increase of 7.7%. 
 
Number of people tested 
As with the Bophelo! mobile clinics, the unit costs per person actually tested have been 
calculated for the New Start Centres. Since most costs are fixed, the unit cost is highly 
dependent on the number of people actually tested.  A sensitivity analysis was performed, 
increasing and decreasing the number of people tested by 10% and 20%.  The results are 
shown in the Table below. 
Table 15: Overview of unit costs with increase/decrease in number of people tested 
 
Difference in 
number of 
people tested 
Total 
number of 
people 
tested 
Per person 
cost N$ 
Per 
person 
cost US$ 
% change 
per unit 
cost 
20% less 
people tested -14,029 56,114 593.56 70.42 21.0% 
 
10% less 
people tested -7,014 63,129 536.39 63.64 9.3% 
actual number 
tested 0 70,143 490.64 58.21 0.0% 
 
10% more 
people tested 7,014 77,157 453.22 53.77 -7.6% 
 
20% more 
people tested 14,029 84,172 422.03 50.07 -14.0% 
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The calculation includes the increased or decreased costs of the test kits, and a pro rata 
inclusion or exclusion of the category ‘other operational costs’, depending on the 
increased or decreased number of people tested. The staff and facility costs have been 
kept stable, as it is assumed that there is capacity available to accommodate these 
changes in volume. As we saw with the Bophelo! clinics, the unit costs decrease with an 
increase in scale. 
 
4.6 Sources of funding 
The funding for the New Start Centres originates fully from the international and national 
public sector: 
 
- International donor: PEPFAR through USAID provides funding for the marketing 
activities (through USAID’s partner Nawa Life) and the test kits (through USAID’s 
partner SCMS). In addition, PEPFAR provides all funding to IntraHealth to cover the 
running costs and overheads associated with the New Start Centres. The estimated 
value of the contribution in 2009, including direct payments to SCMS and NAWA 
life is N$ 30,373,403 / US$ 3,603,426. 
 
- Domestic donor: a number of the New Start Centres receive funding from faith-
based or community organisations. Unfortunately the extent of the funding is not 
available, but an estimate was provided by New Start of 5.0% of the operational 
costs, which is estimated at N$ 879,600 / US$ 104,354. In addition, the costs of 
depreciation of the offices are borne by the owners of the integrated centres, 
which is estimated at an additional N$3,162,205 / US$ 375,156. In total the 
contribution of the external donors is estimated at N$ 4,041,806 / US$ 479,510. 
 38 
5. Comparison of fixed site and mobile screening 
5.1. Introduction 
This chapter compares the two different modes of operations: mobile HIV screening and 
fixed site screening. Caution should be taken when drawing conclusions on the basis of 
this information, as this research focuses on costs, and has not attempted to monetise the 
benefits of each approach. In addition, the only option to compare the costs between the 
two models is to compare on a per person tested basis. However, the unit cost is sensitive 
to the number of people tested, a variable that could change throughout the year for both 
modes of operation. 
 
5.2. Comparison of unit costs 
The table below shows the per unit cost of both operations, based on the numbers of 
people tested. 
 
Table 16: Comparison of unit costs 
  Bophelo! (US$) New Start (US$) 
Cost per patient screened for HIV* 60.59 58.21 
Total cost divided by the number of patients 
screened for the first time for HIV* 262.65 NA** 
Total cost divided by the number of patients 
identified as HIV positive 578.12 557.09 
Total costs divided by the number of patients 
newly identified as HIV positive 737.41 NA** 
* excluding clients who refused HIV testing at Bophelo! clinics. This also excludes any costs of non-HIV 
wellness tests  
 ** cannot be calculated because New Start did not have data on first time testers 
 
 
This overview shows that the New Start average 2009 unit cost is 3.9% lower than the 
Bophelo! average cost during March until December 2009. This difference is equal to the  
higher price that the Bophelo! organisation pays for the test kits in comparison to 
IntraHealth39.   
 
Both the Bophelo! and New Start costs exclude any costs incurred by the person being 
tested.  These are essentially zero in the Bophelo! model, as the employee is given time 
off from work for testing by his employer, and the test clinic is immediately available at 
the work site.  There may be some cost to the employer, who continues to pay wages 
during the brief time required for the test, but no cost to the worker.  A patient who seeks 
testing at a New Start clinic must travel to the clinic site.  In a sparsely populated country 
like Namibia, such costs can be high, and include taxi fare or petrol, as well as possible 
time lost from work.  In effect, Bophelo! internalizes the transport costs which must be 
incurred by the patient in the New Start model. 
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 The difference in the unit cost is US$ 2.35. Bophelo! pays per person tested US$ 2.43 more for a test kit 
(incl.10% wastage). 
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5.3. Comparison of cost categories 
 
Table 17: Comparison of cost categories 
 Category Bophelo! New Start 
Total employment cost, consisting of: 37.3% 41.4% 
Programme mgt / management time* 18.9% 5.6% 
Staff cost 18.4% 35.8% 
Vehicle related costs (depreciation, fuel, 
maintenance) 19.7% 0.0% 
S&T (travel) 15.6% 1.6% 
Test kits 10.5% 6.3% 
Marketing 9.8% 4.5% 
Overhead 6.5% 18.0% 
Quality control 0.6% 1.1% 
Other operating costs 0.0% 17.9% 
Building related costs (depreciation)** 0.0% 9.2% 
Total 100.0% 100.00% 
*This category combines the Bophelo! cost categories of ‘Programme management’ and ‘Management time’ 
** This category includes rent, maintenance of buildings, and other operational costs. Unfortunately it was 
not possible to obtain further detailed information on this cost category. 
 
There are some striking differences and similarities between the  cost categories for the 
two organisations: 
- Total employment cost: for both organisations the employment costs are around 
40% of total costs. This is lower than the average % of employment costs reported 
in other studies (see section 2.2). 
- Travel related costs: Unsurprisingly, the costs for vehicles (19.7%) and staff travel--
---including accommodation and overtime (15.6%) are a high percentage of 
Bophelo!’s overall costs. 
- Overhead: IntraHealth’s overhead is 18.0%, nearly three times as high as the 
Bophelo! overhead rate of 6.5%. Both organisations have reported that this rate 
excluded any costs for management, which is already included in the employment 
costs outlined above.   It is possible that the capture of overhead costs is more 
complete for New Start because of the rigorous USAID accounting rules.  
- Other operating costs: IntraHealth has reported a high percentage of costs in the 
‘Other operating costs’ category. Unfortunately it was not possible to separate this 
category further and it has therefore not been possible to further analyse this 
category. 
- Test kits: as indicated before, IntraHealth was able to procure the test kits at a 
reduced price due to the larger scale of its operation and its relationship with the 
USAID-sponsored Supply Chain Management System. This is also evidenced in the 
higher share of the cost of test kits in the Bophelo! operation.  Due to the relatively 
small size of the operation, Bophelo! has not been able to buy in bulk and has thus 
not been able to access the same prices as IntraHealth. As a consequence, USAID 
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pays N$ 28.09 / US$ 3.33 per test kit, whereas PharmAccess pays N$ 46.75 / US$ 
5.55 per test kit40, a difference of 40.0%. 
- Marketing: Bophelo!’s marketing costs are more than double the share of New 
Start’s marketing costs. This could be attributed to the fact that NABCOA employs 
one full-time marketing person, which constitutes nearly 70% of all marketing 
costs. 
- Quality control: New Start’s costs for quality control (as a proportion of total costs) 
are double relative to Bophelo!’s. This is purely due to the fact that the medical 
technicians must travel out to the New Start sites, which increases the costs of S&T 
with regards to quality control.  Because the Bophelo! vans are based in Windhoek, 
they are readily available to NIP inspectors without any travel costs. 
 
5.4. Contribution of public and private sector 
The New Start clinics are solely funded by international and national donors, whereas the 
Bophelo! operation is one-third funded by private, local companies. The following table 
provides an overview of the costs funded by public (including domestic and international 
donors) and private funding. 
 
Table 18: Public and private contribution 
 Public (US$) Private (US$) 
Bophelo! 193,458 116,993 
Bophelo! % 62.3% 37.7% 
New Start 4,082,936 0.00 
New Start % 100.00% 0.00% 
 
The unit costs to the public sector for testing one person in the Bophelo! clinic are 35% 
lower than the cost to the public sector of testing one person in the New Start Centres. 
This is also illustrated in the table below. 
 
Table 19: Unit costs to the public sector 
 Bophelo! (US$) New Start (US$) 
Full unit cost 60.59 58.21 
Private sector unit cost 22.83 0.00 
Net public sector / donor unit 
cost 37.76 58.21 
 
5.5. Rate of follow up 
Unfortunately, for both organisations there is no information available on the number of 
patients actually pursuing follow up treatment or HIV. However, IntraHealth data confirms 
that 11.8% of their testers re-visit the clinic for follow-up tests.  
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 Excluding any costs for wastage. 
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5.6. Target groups / groups reached 
Bophelo!’s main target group are employees of national firms. This is reflected in the 
demographic data: 55.0% are between the age groups of 25 and 39.  
 
Of the total population tested in the Bophelo! clinics, 64.2% are male. In comparison, 
42.9% of the people tested at the New Start centres are male and 57.1% are female.  
Employment at the sites visited by Bophelo! is skewed towards males, but the results 
suggest that mobile multi-disease screening clinics may be an effective way to reach males 
reluctant to access New Start centres or unwilling to believe they are at risk of HIV 
infection.  
 
Data on Bophelo! shows that during the rural pilot in Nov-Dec, the clinics reached a large 
proportion of people that had never tested before. This is a clear advantage of using 
mobile services: the mobile clinics are able to access areas where no VCT services are 
available.  
 
Although only a limited comparison can be made with New Start Centres due to a lack of 
data on demographics, the above information suggests that mobile clinics have the 
opportunity to attract hard to reach target groups, such as dispersed rural populations.  In 
addition, by bringing the test clinic to the work site, and screening for multiple diseases 
and conditions, Bophelo! makes it easier for those who are reluctant to be seen testing at 
a facility that provides only HIV testing.  
5.7. Conclusions 
 
 What is the full cost of operating a mobile, multi disease screening program in 
Namibia?   
o The table below provides the cost for HIV screening and for full wellness 
screening, and the cost of New Start Centres: 
Table 20: Comparison of unit costs of Bophelo! HIV screening, Bophelo! full wellness screening 
and New Start Centre 
 
Bophelo! 
Only HIV 
screening (US$) 
Bophelo! 
Full wellness 
screening (US$) 
New Start 
(US$) 
Full operating cost 310,451 375,530 4,082,936 
Cost per patient screened*   65.49  
Cost per patient screened ** 60.59 69.72 58.21 
Costs divided by the number 
of conditions identified   86.49  
Cost divided by the number 
of persons identified with 
one or more condition  129.49  
Total cost divided by the 
number of patients identified 
as HIV positive 578.12  557.09 
*including clients that refused HIV testing, but did undertake wellness testing 
**excluding clients that refused HIV testing 
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 What is the value of the private (employer fee) and public (donors and Namibian 
Government) contributions to the cost of the Bophelo! program?  
o The private sector provides 37.7% of the costs (N$ 986,138 / US$ 116,993). 
o The public sector, including foreign donors provides 62.3% of the costs (N$ 
1,630,666 / US$ 193,458). 
 
 Is mobile screening more or less efficient than fixed site screening for HIV infection?  
o Per person tested, mobile screening is 4.0% more expensive than fixed site 
testing. This difference is approximately equal to the higher prices paid for 
HIV test kits. 
o However, the stated per patient cost does not include the patient’s cost of 
travel to get to a clinic, which in the case of Bophelo! is zero.  
o In terms of leveraging private resources, Bophelo! is more efficient: 
IntraHealth does not use private resources, whereas the Bophelo! 
operation is one third funded by local Namibian companies.  The net cost 
to the public sector per patient screened at Bophelo! is currently lower 
than at New Start because of these employer payments. 
 
 Is Bophelo! more effective at reaching out to groups that are unlikely to seek VCT?   
o As there is only limited data available on the demographics of the people 
reached through the New Start Centres, it is difficult to make this 
comparison.  
o However, the data does show that Bophelo! has been effective at reaching 
out to groups that are unlikely to seek VCT, such as rural employees with 
limited access to VCT services.  Screening at work sites also reaches a larger 
proportion of males than are screened at fixed site VCT centers. 
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6. Discussion 
6.1. Introduction 
This research has provided interesting findings and a unique comparison between fixed 
site VCT and mobile VCT. This chapter will highlight some further thoughts and possible 
implications of the findings. 
 
6.2. Discussion 
 
Private sector contributions 
Local Namibian companies have provided 37.7% of all costs of the Bophelo! operation, 
dropping the public sector cost per patient screened below that for fixed site VCT (New 
Start). In Namibia, employers have been willing to pay over 1/3 of the cost of a screening 
program delivered to the work site. 
 
It would now be interesting to follow the Bophelo! project over the next few years to see 
if local companies continue to be willing to pay for screening for their employees on a 
regular basis. 
 
Cost to the public sector 
When the contribution by private sector employers is deducted from total cost, and only 
the actual cost to the public sector is considered, providing VCT through the Bophelo! 
programme has a lower cost to the public purse than fixed site VCT.  
 
 
Target groups 
Mobile clinics have the option to travel to areas where no VCT services are available. In 
addition, the Bophelo! clinics are flexible in their operational hours and are willing to open 
after normal clinic hours. Also, the Bophelo! clinic presence at the work site and 
arrangements with employers ensures that employees can test during working hours at 
no cost to the employee.  Testing at work sites reaches proportionately more males, and 
the multi-disease aspect of Bophelo! testing enables it to attract workers who may not 
think they are at risk of HIV infection or who fear “self-identifying” by seeking out testing 
services at a site that only screens for HIV.  
 
 
Should New Start run mobile clinics? 
This research shows that the additional costs of mobile clinics are relatively low compared 
to the fixed site costs of IntraHealth, and that difficult to reach target groups can be 
accessed.   New Start might want to operate mobile clinics as well, but should also charge 
employers in order to minimize public sector costs, as Bophelo! has done. 
 
Implementation in other countries 
There is no reason why the mobile multi-disease screening approach should not work in 
other countries. Although one of the original reasons to start Bophelo! in Namibia was the 
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low population desnity, most people tested were actually based at formal sector 
workplaces in  cities where New Start Centres are available.  
 
Further use for the mobile clinics – rural areas 
The research has shown that in rural areas people, a particularly large portion of the 
patients have never tested before. To reach these target groups, use of mobile VCT clinics 
should be expanded. The difficulty will obviously be that there are fewer employers (or 
employers with fewer employees), reducing the available employer payments.  Mobile 
testing programs in rural areas will generally require a higher average level of public 
subsidy than shown here. 
 
Outsourcing 
Although Bophelo!’s mobility imposes some higher costs, the unit cost per patient tested 
for HIV is only slightly higher that at New Start.  And the full screening program for other 
diseases is included at a modest additional cost.  The private management of Bophelo! 
facilitates preventive maintenance and flexible staffing that would be difficult for MOHSS.  
Government of Namibia contracting with Bophelo! or a similar mobile multi-disease 
testing organization could be an economical and effective public private partnership  
 
Wellness testing vs just HIV testing 
The incremental cost of providing wellness testing at Bophelo! is only N$ 95.67 / US$ US 
11.35. Bophelo! screens for 9 diseases or conditions, and 50.6% of those screened show 
evidence of at least one risk factor or disease.  Yet only 10% of those screened were 
infected with HIV.  There is increasing recognition of the burden of other chronic diseases. 
Bophelo! is an efficient way to get these Namibians into monitoring and treatment in a 
timely fashion. 
 
Funding 
The Bophelo! programme is still dependent on donor funding, although employer 
payments reduce the required public/donor subsidy below that currently required for 
New Start.  In the long run, Bophelo! like programs will require continued public subsidy, 
but this is a sound investment so long as the subsidy per person tested is below the unit 
cost of publicly funded fixed-site facilities. 
 
6.3. Conclusion 
For a small increment in total cost (compared to fixed site HIV VCT testing), Bophelo! 
brought multi disease screening to work sites and isolated rural populations.  After taking 
into account the fees paid by employers, the cost to donors and the public sector for each 
person tested was lower than in fixed site HIV testing fully supported by 
Government/donor funds. Mobile multi disease testing clinics should be expanded in 
Namibia and employers should continue to pay a portion of the cost.  Contracting for 
mobile screening services, which require financial and operational flexibility, could be an 
important public private partnership advancing Namibia’s health objectives.  
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Appendix Five 
 
Model and user guide 
May 2, 2010 
 
To the User: 
 
This workbook was created to provide a reference for other public health officials and 
accountants around the world to use for their own calculations and modeling of the cost 
of testing programs, particularly VCT for HIV.  It was drafted while keeping in mind the 
ability for future users to adapt inputs, outputs and assumptions to their needs.  The 
original structure of the current model was created as part of the study, “Comparison of 
Key Unit Costs and Outcomes for Mobile and Fixed Site Screening/Testing Programs in 
Namibia.”  
 
The inputs used in this model were supplied through a combination of accounting data  
and interviews with program managers..  The “Cost Elements” tab was designed based on 
the costs identified in the study design.  This provided our team the direction needed to 
acquire the specific data to answer the questions listed in the study design.  The cost 
section is organized around several components of the specific Namibia VCT programs, 
but can be modified to reflect different VCT program designs 
 
Cost and activity data should be collected for the same time period.  Cost data should be 
based on actual expenditures, not budgets. 
 
Input Parameters 
 
In this model, Colum E details costs for the Bophelo! mobile VCT program (which included 
testing for diseases in addition to HIV), and for the  New  Start program of fixed site VCT 
clinics. 
 
The model requires inputs based on costs (local currency) and outcomes of each type of 
testing facility.  As the model currently stands, there are several sample line items that the 
user can use which were based on the Namibia study, but these can also be edited and 
adapted for another costing project.  IF not needed, a row should be left blank but not, 
deleted —formulas in the model are tied to specific rows that may not be readily visible to 
all users. 
 
‘VCT Cost Elements’ (Tab 1) 
 
Operations (cells E6:24, and F6:24) 
Input the costs for each of the items it takes to run the VCT facility.   You will see that 
there are several cells with “n/a.”  This serves as an instruction to the user to be critical 
about which costs to include in the model for fixed site or mobile VCT programs, and 
which to leave out.   If certain program elements are missing, the use may wish to leave 
additional cells blank. 
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The user will need to determine the expected useful life of mobile testing vans or fixed  
facilities.  In Namibia, vehicle useful life was set at five years.   
 
For each activity, the model applies an overhead rate to all of the direct costs for the 
activity.  Where this was not available, we used an estimate (30%) based on comparable 
activities for which overhead costs are calculated 
 
Marketing (cells E31:35, and F31:35) 
Input the costs for each of the items it takes for marketing and promotion.  If marketing 
for the program is only part of one person’s job description, determine the percentage of 
that person’s time dedicated to marketing and multiply this by salary in order to find the 
appropriate input.  Also, if an institution has an overall budget for media purchase or 
materials and VCT promotion is only a portion of the work, determine the appropriate 
percentage and multiply this by the budget to identify the appropriate input for the 
model. 
 
Program Management (Cells E41:69, and F41:69) 
In Namibia, operating costs were split between two organizations, with one organization’s 
costs shown under “operations” and the other here.  If a single organizations is 
responsible for all portions of program operations and management, tone section can be 
used for all relevant cost data, and the other left blank.  The input labels in the current 
model were based on cost elements in Namibia, but once the user can adapt individual 
lines or add lines with additional cost elements. 
 
Quality Control (Cells E76:83, and F76:83) 
In Namibia, these functions were performed by a separate (parastatal) organization. Costs 
in this section should include quality assurance and certification of VCT.  
 
 
‘People Tested’  (Tab 2) 
 
Hopefully, the testing program will maintain these data items in aggregate, or have 
anonymous files on each person tested.  The measures shown below can then be readily 
determined without need to obtain personally identified data on persons testing positive. 
Line Item Instructions 
Number of people screened (B4; D4) 
 
Basic input for total number screened.  If 
multiple sources of data, add up totals on 
a separate tab and ensure that the final 
amount comes in these cells. 
 
Number of people tested for HIV (B5; D5) 
 
 
This will be an important distinction to 
make as you collect your data.  If you do 
not have enough data to make this 
distinction, ensure that “Number of people 
tested for HIV” is accurate before 
estimating a number for the “first time” 
Number of people tested for HIV for the 
first time (B6; D6) 
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value.  Be sure to state any assumptions 
you make in the comment section. 
 
Number of people tested positive (B7; D7) 
 
Most programs may not make this 
distinction.  The important thing is to 
obtain the number of people who test 
positive.  In a VCT program, it is unlikely 
that those who have previously tested 
positive will test again. 
 
Number of people tested positive for the 
first time (B8; D8) 
 
Number of people tested positive for the 
first time and never tested before (B9; D9) 
 
 
‘Contributions’ (Tab 3) 
 
Private Sector 
One goal of the Namibia study was to determine the proporetion of Bophelo! program 
costs carried by fees charged to participating employers.  For VCT programs that chage a 
testing fee, a similar calculation could be performed. In this tabk, list the separate 
institutions that are contributing to the respective VCT program, and then input the 
appropriate amount (in local currency) for their contribution.  Also note the source of data 
used for each entry.  
 
Public Sector 
The Ministry of Health (MOH) in the respective nation will likely have data on how much 
they are contributing to either program.  For example, the  MOH may be providing test 
kits, or some of the staffing for the center.  However, it will be important to acknowledge 
if any other Ministries or Departments in the country are also contributing money and 
listing them here.  In Namibia, this contribution came from the para-statal National  
Institute of Pathology 
 
Domestic Donor 
If there are local NGOs or other organizations that are contributing to the project, either 
in-kind services or cash, list them here.  If In-kind services, make an approximation for 
their contribution and be sure to note how you came to that calculation. 
 
International Donor 
Global Fund to Fight AIDS, TB and Malaria, USAID, PEPFAR, DFID, Gates Foundation, and 
other donors from outside the country can be listed here.  This may include direct cash 
contributions, or the value of certain items listed in Tab 1 which are contributed by the 
donor.  Keep careful notes showing which portions of Tab 1 lines are reflected in these 
cells. 
 
 
Output Tables and Charts 
 
‘Primary Questions’ 
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Provides table summary of answers to commonly asked questions about both delivery 
models.  User can add more components to this section with corresponding formula 
calculations, and use this as an Executive Dashboard for senior stakeholders on each 
project. 
 
‘Mobile VCT Costs’ and ‘Fixed VCT Costs’ 
Displays the distribution of costs of both types of VCT in pie chart form.  
 
’Cost per Patient of VCT delivery methods’ 
Compares Mobile VCT to Fixed VCT across column chart. 
 
 
Please consider the following when making any adaptations and in reviewing results: 
 
1. Determine what you are trying to answer.  Put these in the “Primary Questions” 
tab and determine what is needed to calculate the value for each of these 
questions. 
2. State your assumptions. The assumptions can either be listed directly in the tabs 
provided or on a separate tab.  This may take the longest amount of time as you 
review the inputs and aim to fill in the gaps.  The gaps we filled in our data were 
based on reasonable assumptions based on our experience in the field on previous 
global health projects.  Be sure to also state where you are making assumptions so 
that another user can trace back and re-create your work if necessary. 
3. If you add more formulas and rows to the worksheets, ensure your formulas work. 
Utilize the “Formula Auditing” functions and Name Assignment features of Excel in 
order to keep consistent data across different tabs.  Also make sure that there is 
no double counting of rows, which can create a multiplier effect for the costs. 
4. Use your common sense when reviewing the results. Compare results on your 
personal experience with the projects.  If you find that it costs you over US$20,000 
per patient for operating a multi disease screening program, and this contradicts 
your own personal experience, then you may have a formula error. 
 
 
